Key result
Interferon-based HCV treatment was associated with a significantly higher risk of echocardiographic pulmonary hypertension (OR 5.65) in patients with HIV-HCV coinfection.
Why the study?
Does interferon-based HCV treatment increase the risk of echocardiographic pulmonary hypertension in HIV-HCV coinfected patients?
Cohort (n=68)
No
Does interferon-based HCV treatment increase the risk of echocardiographic pulmonary hypertension in HIV-HCV coinfected patients?
In HIV-HCV coinfected patients, interferon-based HCV treatment and duration of HCV diagnosis are associated with an increased risk of echocardiographic pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May warrant PH monitoring with interferon in HIV-HCV coinfection; leaves open causal confirmation in prospective studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sangal et al. (2014) conducted a cohort in HIV-HCV coinfection (n=68). Interferon-based HCV treatment vs. No interferon treatment was evaluated on Risk of echocardiographic pulmonary hypertension or right ventricular dysfunction (OR 5.65, 95% CI 1.07-29.93, p=0.042). Interferon-based HCV treatment was associated with a significantly higher risk of echocardiographic pulmonary hypertension (OR 5.65) in patients with HIV-HCV coinfection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: